Cargando…
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer(1). However, clinical responses to FGFR inhibitors have remained variable(1–9), emphasizing the need to better understand which FGF...
Ejemplares similares
-
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
por: Zingg, Daniel, et al.
Publicado: (2022) -
Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system
por: Klarenbeek, Sjoerd, et al.
Publicado: (2020) -
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
por: Bhin, Jinhyuk, et al.
Publicado: (2023) -
Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors
por: Bhin, Jinhyuk, et al.
Publicado: (2023) -
Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer
por: Annunziato, Stefano, et al.
Publicado: (2019)